2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-114285
    L-161638 150484-73-4 98%
    L-161638 is a potent, selective and orally active AT2 receptor antagonist. L-161638 can be used for the research of cardiovascular disease, such as hypertension.
    L-161638
  • HY-114293
    Acetyl coenzyme A 72-89-9 98%
    Acetyl-coenzyme A (Acetyl-CoA) is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A, regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A is also a key precursor of lipid synthesis.
    Acetyl coenzyme A
  • HY-114424
    H-Ile-Pro-Pro-OH 26001-32-1 98%
    H-Ile-Pro-Pro-OH, a milk-derived peptide, inhibits angiotensin-converting enzyme (ACE) with an IC50 of 5 μM. Antihypertensive tripeptides.
    H-Ile-Pro-Pro-OH
  • HY-114538
    Asobamast 104777-03-9 98%
    Asobamast is a potent, orally active antiallergic agent that inhibits ige mediated passive pulmonary allergic responses in rats (ED50=4.7 mg/kg) and inhibits antigen-induced mediator release from sensitized guinea pig lung fragments.
    Asobamast
  • HY-114587
    RS 93427-007 105284-21-7 98%
    RS 93427-007 is an orally active prostacyclin stable mimetic agent. RS 93427-007 can be used for the research of cardiovascular disease, such as atherosclerosis.
    RS 93427-007
  • HY-114593
    ent-8-iso Prostaglandin F2α 159812-83-6 98%
    ent-8-iso Prostaglandin F2α (ent-15-F2t-IsoP) is a potent vasoconstrictor of porcine retina and cerebral microvessels with EC50 values of 30.6 and 53.5 nM, respectively.
    ent-8-iso Prostaglandin F2α
  • HY-114603
    Efegatran 105806-65-3 98%
    Efegatran (LY 294468) is an inhibitor for thrombin, which inhibits aggregation of platelets, and exhibits anticoagulant and antithrombotic activities.
    Efegatran
  • HY-114630
    Protokylol 136-70-9 98%
    Protokylol (Caytine; JB-251) is a beta-adrenergic receptor agonist and TRPV1 agonist. Protokylol is used as a bronchodilator.
    Protokylol
  • HY-114643
    (Rac)-Tovinontrine 1430840-90-6 98%
    (Rac)-Tovinontrine ((Rac)-IMR-687) is a phosphodiesterase 9 (PDE9) inhibitor that increases cyclic guanosine monophosphate (cGMP) levels. (Rac)-Tovinontrine is promising for research of thalassemia.
    (Rac)-Tovinontrine
  • HY-114660
    9,11-Methane-epoxy prostaglandin F1α 72517-81-8 98%
    9,11-methane-epoxy Prostaglandin F1α (9,11-Epoxymethano PGH1; 9,11-methane-epoxy PGF1α) is a derivative of prostaglandin H1. 9,11-methane-epoxy Prostaglandin F1α induces aggregation of isolated rabbit platelets (EC50=0.88 µM) and contraction of rabbit aortic strips (EC50=0.11 µM). 9,11-methane-epoxy Prostaglandin F1α induces contraction of isolated guinea pig tracheas (EC50 = 3.4 µM).
    9,11-Methane-epoxy prostaglandin F1α
  • HY-114666
    Trimoxamine hydrochloride 7082-27-1 98%
    Trimoxamine hydrochloride (NDR-5523A) is an antihypertensive drug with hypotensive activity. Trimoxamine hydrochloride can be used to inhibit hypertension-related diseases. Trimoxamine hydrochloride lowers blood pressure by inhibiting vasoconstriction. Trimoxamine hydrochloride plays an important role in the management of cardiovascular diseases.
    Trimoxamine hydrochloride
  • HY-114687
    5,7-Dihydroxy-11-ketotetranorprostanoic acid 24379-94-0 98%
    5,7-Dihydroxy-11-ketotetranorprostanoic acid is a urinary metabolite of prostaglandin F2α and precursor to tetranor-PGF metabolites, exhibits hardly activity in blood pressure assay and smooth muscle stiumulation assay.
    5,7-Dihydroxy-11-ketotetranorprostanoic acid
  • HY-114751
    16,16-Dimethylprostaglandin E1 41692-15-3 98%
    16,16-Dimethylprostaglandin E1 (16,16-dimethyl-PGE1) is a PGE1 (HY-B0131) analog, induces bronchoconstrict and vascular smooth muscle contractions and suppresses the indomethacin induced cellular elongation.
    16,16-Dimethylprostaglandin E1
  • HY-114761
    Prostaglandin F2α dimethyl amine 67508-09-2 98%
    Prostaglandin F2α dimethyl amine is a Prostaglandin F2α (HY-12956) derivative. Prostaglandin F2α dimethyl amine is an antagonist for Prostaglandin F receptor (FP). Prostaglandin F2α dimethyl amine blocks the cardiovascular responses induced by orexin and Arachidonic acid (HY-109590).
    Prostaglandin F2α dimethyl amine
  • HY-114792
    15-Methylprostaglandin E1 35700-26-6 98%
    15-Methylprostaglandin E1 (15S-15-Methyl-PGE1) exhibits a positiv chronotropic effect, increases the heart rate and levels of nicardipine.
    15-Methylprostaglandin E1
  • HY-114898
    ML404 1826026-00-9 98%
    ML404 (Compound 38) is an inhibitor of the mitochondrial permeability transition pore (mtPTP), which can suppress mitochondrial swelling (EC50=4.9 nM) and only disrupts mitochondrial coupling (an adverse effect) at concentrations > 100 μM. ML404 can be utilized in research related to multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), muscular dystrophies (MD), myocardial infarction, and stroke.
    ML404
  • HY-114920
    Piprofurol 40680-87-3 98%
    Piprofurol is a calcium channel inhibitor. Piprofurol inhibits the calcium-induced contractions in isolated potassium depolarized preparations of rat aorta in a concentration-dependent manner and relaxes the K+-induced contraction of the dog coronary artery and the rabbit basilar artery. Piprofurol exerts a negative inotropic effect on guinea-pig papillary muscle, with the EC50 of 5 μM.
    Piprofurol
  • HY-114947
    9-deoxy-9-methylene Prostaglandin E2 61263-32-9 98%
    9-deoxy-9-methylene Prostaglandin E2 (9-deoxy-9-methylene PGE2) is a stable, isosteric analog of PGE2. 9-deoxy-9-methylene PGE2 retains the biological profile of PGE2 with fewer side effects. In the rat 9-deoxy-9-methylene PGE2 is equipotent to PGE2 in decreasing blood pressure. It also stimulates the gerbil colon and primate uterus at the same potency as PGE2.
    9-deoxy-9-methylene Prostaglandin E2
  • HY-114952
    SM-32504 185539-34-8 98%
    SM-32504 is an effective ACAT inhibitor that can significantly reduce serum cholesterol levels in mouse models fed with high-fat and high-cholesterol diets. SM-32504 can be used for research on hypercholesterolemia and atherosclerosis.
    SM-32504
  • HY-114953
    BMS-248360 254737-87-6 98%
    BMS-248360 is a potent and orally active dual antagonist of both angiotensin II receptor (AT1) and endothelin A (ETA) receptor, with Kis of 10 nM and 1.9 nM for hAT1 and hETA receptor, respectively. BMS-248360 displays hypertensive effects.
    BMS-248360
Cat. No. Product Name / Synonyms Application Reactivity